Osivax

Osivax is a clinical-stage biopharmaceutical company developing a portfolio of differentiated influenza vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses, thanks to its novel, self-assembling nanoparticle platform technology, oligoDOMTM. The company’s lead candidate, OVX836, is a broad-spectrum influenza A vaccine candidate currently in Phase 2b clinical trials with over 4,000 volunteers tested and encouraging efficacy proof of concept data. By combining OVX836 with standard flu vaccines, Osivax is advancing toward a best-in-class seasonal flu vaccine to prevent all strains of influenza. Osivax collaborates with leading global health agencies and top-tier pharmaceutical companies, reinforcing its mission to prevent all types of seasonal and pandemic influenza. The company will expand into other infectious disease indications through combinations and collaborations worldwide.